Comparative Bioavailability and Effect of Food on CMX001 in Healthy Volunteers

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the bioavailability of CMX001 when administered as a tablet vs a solution and to determine the effect of a high-fat meal on CMX001 bioavailability.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Chimerix
• Collaborator: National Institutes of Health (NIH)
• Treatments: Brincidofovir

Criteria

Inclusion Criteria:

• Healthy males and non-childbearing females 18-55 years old

Exclusion Criteria:

• Use of an investigational drug and/or treatment within 30 days prior to enrollment.

• Positive HIV, Hepatitis B or Hepatitis C test result

• Tobacco user

• History of GI disease or disorder

• History of positive fecal occult blood test (FOBT)

• Body Mass Index (BMI) > 30 or < 18, or body weight < 50 kg

• Prior abdominal or pelvic surgery